Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis

被引：0
作者：
Stoiber, Alina [1 ,2 ]
Gray, Gwen [1 ]
Sailer, Gudrun [2 ]
Huf, Wolfgang [3 ]
Tonna, Antonella [1 ]
机构：
[1] Robert Gordon Univ, Sch Pharm Appl Sci & Publ Hlth, Garthdee Rd, Aberdeen AB10 7QB, Scotland
[2] Vienna Healthcare Grp, Hosp Pharm, Clin Hietzing, Vienna, Austria
[3] Karl Landsteiner Inst Clin Risk Management, Vienna, Austria
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2025年 / 47卷 / 02期
关键词：
COVID-19 drug treatment; Drug-related problems; Medication review; Nirmatrelvir and Ritonavir drug combination; Patient safety; COMMUNITY PHARMACIES; MEDICATION REVIEWS; IMPACT;
D O I：
10.1007/s11096-024-01852-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
BackgroundPaxlovid (R) (nirmatrelvir and ritonavir) is the only licensed oral antiviral for COVID-19. Ritonavir is a potent inhibitor of cytochrome P450 enzymes causing numerous drug-drug interactions (DDIs).AimTo describe the frequency, type, and severity of detected drug related problems (DRPs) associated with Paxlovid (R).MethodThis study involved a retrospective quantitative analysis including all patients prescribed Paxlovid (R) at a public hospital in Vienna, Austria. Data were collected from the patients' records by a clinical pharmacist. A customised, piloted data collection form was used. A sample of data was checked for consistency by an independent clinical pharmacist. Any DDI and severity classification was recorded using an established interaction checker tool. Dosage adjustments due to renal impairment were recorded.ResultsOne hundred twenty-two of 140 patients (87.1%) required interventions to prevent DRPs. Pharmacists' intervention at dispensing was needed in 63.6% (n = 89) of cases. In 3 (2.1%) patients, Paxlovid (R) was prescribed despite being contraindicated due to severe renal impairment. The most common were DDIs (n = 80; 57.1%). Renal impairment and DDIs were noted in 24.3% (n = 34) of cases. A total of 313 DDIs were recorded in 114 (81.4%) patients, with severe interactions in 24 (17%) patients.ConclusionPharmacists' involvement in prescribing highly interacting drugs such as Paxlovid (R) is essential to enhance patient safety.
引用
收藏
页码：471 / 476
页数：6
相关论文
共 32 条
  • [11] Tanne J.H., Covid-19: FDA authorises pharmacists to prescribe Paxlovid, Br Med J, 378, (2022)
  • [12] Traynor K., Québec authorizes pharmacists to prescribe Paxlovid, Am J Health Syst Pharm, 79, pp. 1126-1127, (2022)
  • [13] Bundesministerium für Finanzen. RIS [Rechtsinformationssystem des Bundes]—Rezeptpflichtgesetz—Bundesrecht konsolidiert, Fassung vom 22.03.2023. Bundesministerium für Finanzen. 2023. [Federal Ministry of Finance. RIS (Federal Information System for Laws)—Compulsory Prescription Act—Federal law consolidated, version dated March 22, 2023. Federal Ministry of Finance. 2023.]
  • [14] McHugh M., Interrater reliability: the kappa statistic, Biochem Med (Zagreb), 22, 3, pp. 276-282, (2012)
  • [15] Liverpool COVID-19 Drug Interactions. the University of Liverpool, (2023)
  • [16] Igho-Osagie E., Puenpatom A., Williams M.G., Et al., Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy, J Manag Care Spec Pharm, 29, pp. 509-528, (2023)
  • [17] Kim Y., Ryu J.Y., Kim H.U., Et al., Computational prediction of interactions between Paxlovid and prescription drugs, Proc Natl Acad Sci, 120, (2023)
  • [18] Marzolini C., Kuritzkes D.R., Marra F., Et al., Recommendations for the management of drug-drug interactions between the COVID-19 antiviral Nirmatrelvir/ritonavir (Paxlovid) and comedications, Clin Pharmacol Ther, 112, pp. 1191-1200, (2022)
  • [19] Xiao X., Mehta H.B., Curran J., Et al., Potential drug-drug interactions among US adults treated with nirmatrelvir/ritonavir: a cross-sectional study of the National Covid Cohort Collaborative (N3C), Pharmacotherapy, 43, pp. 1251-1261, (2023)
  • [20] Kieck D., Mahalick L., Vo T.T., Medication-related problems identified and addressed by pharmacists dispensing COVID-19 antivirals at a community pharmacy, Pharmacy (Basel), 11, (2023)
1234